AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18652709 — intervention group
Group type: COMPARATOR
Intervention: Caudal block using 0.5 mL kg(‐1) 0.25% bupivacaine with 0.5 mg kg(‐1) ketamine (Group C)
Number of subjects: 40
Study 15956998 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation
Number of subjects: 716
Study 15956998 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivitamins (B, C, and E)
Number of subjects: 716
Study 15956998 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivitamins including A
Number of subjects: 716
Study 15956998 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 716
Study 12866218 — intervention group
Group type: EXPERIMENTAL
Intervention: Johnson and Toshach technique
Number of subjects: 504
Study 10553833 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% ropivacaine (1%) and 50% lidocaine (2%) with 25 U hyaluronidase per mL
Number of subjects: 100
Study 10553833 — intervention group
Group type: COMPARATOR
Intervention: 50% bupivacaine (0.5%) and 50% lidocaine (2%) with 25 U hyaluronidase per mL
Number of subjects: 100
Study 8656441 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy (cisplatin [100 mg/m2] on day 1, followed by fluorouracil [1000 mg/m2 per day] on days 1-5)
Number of subjects: 194
Study 8656441 — intervention group
Group type: COMPARATOR
Intervention: Immediate surgery with postoperative radiotherapy (50-70 Gy)
Number of subjects: 194
Study 1804657 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone (5 mg)
Number of subjects: 28
Study 1804657 — intervention group
Group type: EXPERIMENTAL
Intervention: Niacin (50 mg)
Number of subjects: 28
Study 1804657 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 6837864 — intervention group
Group type: EXPERIMENTAL
Intervention: Shaving
Number of subjects: 253
Study 6837864 — intervention group
Group type: COMPARATOR
Intervention: Depilatory cream
Number of subjects: 253
Study 31271587 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic training on dry land
Number of subjects: 55
Study 31271587 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined training on dry land
Number of subjects: 55
Study 31271587 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined training in water
Number of subjects: 55
Study 31271587 — intervention group
Group type: COMPARATOR
Intervention: Without training
Number of subjects: 55
Study 28566591 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol (200 mg/day) plus Aspirin (100 mg/day)
Number of subjects: 24
Study 28566591 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (100 mg/day)
Number of subjects: 24
Study 26549616 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimenter-enforced associative encoding strategy
Number of subjects: 0
Study 26549616 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandated rote rehearsal
Number of subjects: 0
Study 26549616 — intervention group
Group type: EXPERIMENTAL
Intervention: Encouraged time and effort toward encoding with strategy choice
Number of subjects: 0
Study 25118156 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Strength Training for Upper Limb (FST-UL)
Number of subjects: 52
Study 25118156 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Strength Training for Lower Limb (FST-LL)
Number of subjects: 52
Study 25118156 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Strength Training (FST)
Number of subjects: 52
Study 25118156 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 52
Study 22975928 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation (DBS)
Number of subjects: 161
Study 22975928 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation (GPi)
Number of subjects: 161
Study 22975928 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation (STN)
Number of subjects: 161
Study 22975928 — intervention group
Group type: COMPARATOR
Intervention: Best Medical Therapy (BMT)
Number of subjects: 161
Study 19383585 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior pericardiotomy
Number of subjects: 410
Study 19383585 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (control group)
Number of subjects: 410
Study 17885895 — intervention group
Group type: EXPERIMENTAL
Intervention: Social Communication Questionnaire (SCQ)
Number of subjects: 49
Study 17885895 — intervention group
Group type: EXPERIMENTAL
Intervention: Developmental Behaviour Checklist‐Autism Screening Algorithm (DBC‐ASA)
Number of subjects: 49
Study 15129422 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefazodone (maximum dose 600 mg/day; average dose 463 mg/day)
Number of subjects: 37
Study 15129422 — intervention group
Group type: COMPARATOR
Intervention: Sertraline (maximum dose 200 mg/day; average dose 153 mg/day)
Number of subjects: 37
Study 15129422 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Nefazodone and Sertraline)
Number of subjects: 37
Study 12489352 — intervention group
Group type: EXPERIMENTAL
Intervention: Weak isometric plantar-flexion at 20% of maximum voluntary contraction
Number of subjects: 15
Study 12489352 — intervention group
Group type: EXPERIMENTAL
Intervention: Weak isometric dorsiflexion at 20% of maximum voluntary contraction
Number of subjects: 15
Study 12489352 — intervention group
Group type: EXPERIMENTAL
Intervention: Test-stimulus intensity
Number of subjects: 15
Study 12489352 — intervention group
Group type: EXPERIMENTAL
Intervention: Smaller test stimuli
Number of subjects: 15
Study 9515532 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary trypsin inhibitor (UTI) administered for 5 consecutive days at a dose of 300,000 units per day
Number of subjects: 16
Study 9515532 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified what intervention was used)
Number of subjects: 16
Study 9515532 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary trypsin inhibitor (UTI)
Number of subjects: 16
Study 8070304 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexfenfluramine 15 mg twice daily for 4 weeks
Number of subjects: 10
Study 3123117 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral etidronate (700‐1400 mg daily for 1 month)
Number of subjects: 17
Study 3123117 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous etidronate (300 mg daily for 5 days)
Number of subjects: 17
Study 31237000 — intervention group
Group type: EXPERIMENTAL
Intervention: Prospectively registered trials
Number of subjects: 151
Study 31237000 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrospectively registered trials
Number of subjects: 151
Study 31237000 — intervention group
Group type: EXPERIMENTAL
Intervention: Not registered trials
Number of subjects: 151
Study 31237000 — intervention group
Group type: EXPERIMENTAL
Intervention: Indeterminate registration trials
Number of subjects: 151
Study 31237000 — intervention group
Group type: EXPERIMENTAL
Intervention: Trials with registration number reported
Number of subjects: 151
Study 28355112 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorambucil plus Rituximab
Number of subjects: 454
Study 28355112 — intervention group
Group type: COMPARATOR
Intervention: Chlorambucil alone
Number of subjects: 454
Study 28355112 — intervention group
Group type: COMPARATOR
Intervention: Rituximab alone
Number of subjects: 454
Study 28355112 — intervention group
Group type: COMPARATOR
Intervention: All treatments
Number of subjects: 454
Study 25658881 — intervention group
Group type: EXPERIMENTAL
Intervention: Prehospital plasma transfusion during air medical transport
Number of subjects: 6
Study 25658881 — intervention group
Group type: EXPERIMENTAL
Intervention: Prehospital plasma transfusion
Number of subjects: 6
Study 23474847 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 4% strontium chloride (TriCalm®)
Number of subjects: 32
Study 23474847 — intervention group
Group type: COMPARATOR
Intervention: Control vehicle
Number of subjects: 32
Study 23474847 — intervention group
Group type: COMPARATOR
Intervention: 1% hydrocortisone
Number of subjects: 32
Study 23474847 — intervention group
Group type: COMPARATOR
Intervention: 2% diphenhydramine
Number of subjects: 32
Study 21484081 — intervention group
Group type: EXPERIMENTAL
Intervention: Single Step Dilatational Tracheostomy (SSDT)
Number of subjects: 120
Study 21484081 — intervention group
Group type: COMPARATOR
Intervention: Guide Wire Dilating Forceps (GWDF)
Number of subjects: 120
Study 17851665 — intervention group
Group type: EXPERIMENTAL
Intervention: High-resolution first-pass myocardial perfusion imaging (HRPI) at 3 T
Number of subjects: 60
Study 16506054 — intervention group
Group type: EXPERIMENTAL
Intervention: Human insulin inhalation powder (HIIP) plus insulin glargine
Number of subjects: 228
Study 16506054 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneously injected insulin (SC insulin) plus insulin glargine
Number of subjects: 228
Study 15179836 — intervention group
Group type: EXPERIMENTAL
Intervention: Carmofur
Number of subjects: 150
Study 15179836 — intervention group
Group type: COMPARATOR
Intervention: Carboquone
Number of subjects: 150
Study 11078261 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticlopidine (250 mg/twice daily) for 72 hours
Number of subjects: 160
Study 11078261 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (250 mg/day)
Number of subjects: 160
Study 11078261 — intervention group
Group type: COMPARATOR
Intervention: Control group (unstable angina patients without ticlopidine)
Number of subjects: 160
Study 8632075 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole 200 mg once daily for 7 days
Number of subjects: 36
Study 8632075 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 1471412 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunopotentiating reconstituted influenza virosomes (IRIVs)
Number of subjects: 100
Study 1471412 — intervention group
Group type: COMPARATOR
Intervention: Alum-adsorbed vaccine (Control)
Number of subjects: 100
Study 6319337 — intervention group
Group type: EXPERIMENTAL
Intervention: Purified form of wheat fibre (10.5 g/d)
Number of subjects: 12
Study 6319337 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 12
Study 2877413 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine
Number of subjects: 18
Study 2877413 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion with isotonic saline
Number of subjects: 18
Study 29953106 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen biomaterial (Collost)
Number of subjects: 75
Study 29953106 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 75
Study 28466619 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical clown present during venipuncture (n=29)
Number of subjects: 53
Study 28466619 — intervention group
Group type: COMPARATOR
Intervention: No medical clown present during venipuncture (n=24)
Number of subjects: 53
Study 28466619 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical clown present
Number of subjects: 53
Study 28466619 — intervention group
Group type: COMPARATOR
Intervention: No medical clown present
Number of subjects: 53
Study 26056101 — intervention group
Group type: EXPERIMENTAL
Intervention: RPT 450 mg
Number of subjects: 153
Study 26056101 — intervention group
Group type: EXPERIMENTAL
Intervention: RPT 600 mg
Number of subjects: 153
Study 26056101 — intervention group
Group type: COMPARATOR
Intervention: RMP 600 mg
Number of subjects: 153
Study 23435121 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural treatment with additional computerized probe procedure for attentional bias modification
Number of subjects: 134
Study 23435121 — intervention group
Group type: COMPARATOR
Intervention: Placebo variant of the computerized probe procedure
Number of subjects: 134
Study 20795418 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide (10 mg every 8 hours)
Number of subjects: 220
Study 20795418 — intervention group
Group type: COMPARATOR
Intervention: Control (no metoclopramide)
Number of subjects: 220
Study 20795418 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide
Number of subjects: 220
Study 20795418 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 220
Study 18408370 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid supplementation, 1 mg/day
Number of subjects: 25
Study 18408370 — intervention group
Group type: COMPARATOR
Intervention: Phenytoin therapy
Number of subjects: 25
Study 18408370 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 25
Study 16677697 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg twice a day
Number of subjects: 25
Study 16677697 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 12873294 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin lispro
Number of subjects: 23
Study 10643696 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment (various second-line drugs including methotrexate, cyclosporine plus MTX, and others)
Number of subjects: 1435
Study 10643696 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1435
Study 8797406 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline (Uniphyl)
Number of subjects: 20
Study 8797406 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol
Number of subjects: 20
Study 1521940 — intervention group
Group type: EXPERIMENTAL
Intervention: CK: carbonated 10% glucose-fructose solution
Number of subjects: 8
Study 1521940 — intervention group
Group type: EXPERIMENTAL
Intervention: NCK: non-carbonated 10% glucose-fructose solution
Number of subjects: 8
Study 1521940 — intervention group
Group type: COMPARATOR
Intervention: CNK: carbonated non-caloric solution
Number of subjects: 8
Study 1521940 — intervention group
Group type: COMPARATOR
Intervention: NCNK: non-carbonated non-caloric solution
Number of subjects: 8
Study 6476044 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary capsulotomy
Number of subjects: 288
Study 6476044 — intervention group
Group type: COMPARATOR
Intervention: Intact capsule
Number of subjects: 288
Study 30878823 — intervention group
Group type: EXPERIMENTAL
Intervention: Social network (stronger social network)
Number of subjects: 147
Study 30878823 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger age
Number of subjects: 147
Study 30878823 — intervention group
Group type: EXPERIMENTAL
Intervention: Current driving status
Number of subjects: 147
Study 29045255 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxing music therapy intervention (20 minutes, 3 times a day for 3 consecutive days)
Number of subjects: 17
Study 29045255 — intervention group
Group type: COMPARATOR
Intervention: Silence (control group)
Number of subjects: 17
Study 26456348 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation-based neonatal resuscitation curriculum
Number of subjects: 33
Study 26456348 — intervention group
Group type: COMPARATOR
Intervention: Lecture-based neonatal resuscitation curriculum
Number of subjects: 33
Study 23884719 — intervention group
Group type: EXPERIMENTAL
Intervention: Poractant alfa
Number of subjects: 215
Study 23884719 — intervention group
Group type: COMPARATOR
Intervention: Beractant
Number of subjects: 215
Study 22052702 — intervention group
Group type: EXPERIMENTAL
Intervention: DRAAAS (dose regimen of artesunate and amodiaquine based on arm span- or age range)
Number of subjects: 68
Study 22052702 — intervention group
Group type: COMPARATOR
Intervention: SDRAA (standard dose regimen of artesunate and amodiaquine calculated according to body weight)
Number of subjects: 68
Study 20210909 — intervention group
Group type: EXPERIMENTAL
Intervention: Recreational football training (F)
Number of subjects: 50
Study 20210909 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance running (R)
Number of subjects: 50
Study 20210909 — intervention group
Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 50
Study 18381226 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural condition with asymmetric visual distractor
Number of subjects: 0
Study 18381226 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirror-reversed condition with asymmetric visual distractor
Number of subjects: 0
Study 15861266 — intervention group
Group type: EXPERIMENTAL
Intervention: Formal IBD education
Number of subjects: 69
Study 15861266 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 69
Study 12181715 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sip feed containing 500 kcal of energy and 16.66 g of protein in addition to daily oral intake
Number of subjects: 60
Study 12181715 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 60
Study 9842606 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to printed advertisements with attractive overweight models
Number of subjects: 0
Study 9842606 — intervention group
Group type: COMPARATOR
Intervention: Exposure to printed advertisements with models who were not overweight
Number of subjects: 0
Study 8076537 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelastine nasal solution 2 sprays per nostril bid
Number of subjects: 247
Study 8076537 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelastine nasal solution 2 sprays per nostril qd
Number of subjects: 247
Study 8076537 — intervention group
Group type: COMPARATOR
Intervention: Chlorpheniramine 12 mg bid
Number of subjects: 247
Study 8076537 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 247
Study 2635353 — intervention group
Group type: EXPERIMENTAL
Intervention: Mexiletine 250 mg i.v. + 200 mg orally followed by 200 mg every 8 h for 48 h
Number of subjects: 32
Study 2635353 — intervention group
Group type: EXPERIMENTAL
Intervention: Mexiletine treatment
Number of subjects: 32
Study 2635353 — intervention group
Group type: COMPARATOR
Intervention: Routine treatment only (Control)
Number of subjects: 32
Study 337854 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine 5 mg or 10 mg alone or with promethazine 6.25 mg, 12.5 mg, or 25 mg
Number of subjects: 270
Study 337854 — intervention group
Group type: EXPERIMENTAL
Intervention: Promethazine 25 mg alone
Number of subjects: 270
Study 337854 — intervention group
Group type: EXPERIMENTAL
Intervention: Promethazine doses larger than 12.5 mg
Number of subjects: 270
Study 337854 — intervention group
Group type: EXPERIMENTAL
Intervention: All drugs (morphine and promethazine)
Number of subjects: 270
Study 30955985 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen plus placebo
Number of subjects: 320
Study 30955985 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen plus baclofen 10 mg
Number of subjects: 320
Study 30955985 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen plus metaxalone 400 mg
Number of subjects: 320
Study 30955985 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen plus tizanidine 2 mg
Number of subjects: 320
Study 29770393 — intervention group
Group type: EXPERIMENTAL
Intervention: Pomegranate consumption
Number of subjects: 0
Study 27127346 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin (12 months treatment, group A)
Number of subjects: 36
Study 27127346 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin (6 months treatment followed by 6 months follow-up, group B)
Number of subjects: 36
Study 27127346 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin (both groups A and B)
Number of subjects: 36
Study 27127346 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 36
Study 23829810 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard essential oil blend
Number of subjects: 192
Study 23829810 — intervention group
Group type: EXPERIMENTAL
Intervention: Customized aromatherapy treatment
Number of subjects: 192
Study 23829810 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 192
Study 22409423 — intervention group
Group type: EXPERIMENTAL
Intervention: Acellular dermal matrix graft (ADMG) with enamel matrix derivative (EMD)
Number of subjects: 19
Study 22409423 — intervention group
Group type: COMPARATOR
Intervention: Acellular dermal matrix graft (ADMG) alone
Number of subjects: 19
Study 19306597 — intervention group
Group type: EXPERIMENTAL
Intervention: CPP-ACP containing products
Number of subjects: 0
Study 17503687 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative mood induction procedure in older adults
Number of subjects: 0
Study 17503687 — intervention group
Group type: COMPARATOR
Intervention: Negative mood induction procedure in younger adults
Number of subjects: 0
Study 15165758 — intervention group
Group type: EXPERIMENTAL
Intervention: Active SLE
Number of subjects: 98
Study 15165758 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly active SLE
Number of subjects: 98
Study 15165758 — intervention group
Group type: COMPARATOR
Intervention: Inactive SLE
Number of subjects: 98
Study 15165758 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects
Number of subjects: 98
Study 12226035 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribavirin treatment
Number of subjects: 49
Study 12226035 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 49
Study 9215181 — intervention group
Group type: EXPERIMENTAL
Intervention: Spontaneous placental removal
Number of subjects: 333
Study 9215181 — intervention group
Group type: COMPARATOR
Intervention: Manual placental removal
Number of subjects: 333
Study 9215181 — intervention group
Group type: EXPERIMENTAL
Intervention: Spontaneous placental removal (subset analysis with ruptured membranes)
Number of subjects: 333
Study 9215181 — intervention group
Group type: COMPARATOR
Intervention: Manual placental removal (subset analysis with ruptured membranes)
Number of subjects: 333
Study 7696831 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT)
Number of subjects: 86
Study 7696831 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study 3667068 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet + Exercise (DE)
Number of subjects: 12
Study 3667068 — intervention group
Group type: COMPARATOR
Intervention: Diet (D)
Number of subjects: 12
Study 31738736 — intervention group
Group type: EXPERIMENTAL
Intervention: Evening primrose oil (1,000 mg daily for 8 weeks)
Number of subjects: 189
Study 31738736 — intervention group
Group type: COMPARATOR
Intervention: Placebo (matching capsules for 8 weeks)
Number of subjects: 189
Study 29621261 — intervention group
Group type: EXPERIMENTAL
Intervention: GOT+IOT
Number of subjects: 129
Study 28636184 — intervention group
Group type: EXPERIMENTAL
Intervention: Bococizumab (150 mg subcutaneously) administered to the abdomen
Number of subjects: 75